Current Issue

VOL 13 NO 4 • May/Jun 2022
This issue’s cover illustration depicts a single SARS-CoV-2 virus casting a long shadow on neutrophils and lymphocytes. Artwork by Alexandra Webber © 2022, DNA Illustrations, Inc., Asheville, North Carolina. EditorialBeth Faiman, PhD, MSN, APRN-BC, AOCN®, FAANImagine this scenario: A patient is scheduled to see you for a routine follow-up appointment. You are co-managing this patient with a physician. In preparation for the encounter, you review the chart and note that the patient obtained surveillance labs and CT scans earlier in the week in preparat...
Research and ScholarshipNada Alsuhebany,(1,2,3) BSPharm, PharmD, BCOP, Jamie Brown,(4) PharmD, MBA, Jacquelyne Echave,(5) and Ali McBride,(5) PharmD, MS, BCPSMalignancy is the second leading cause of death in the United States and was attributed to 44.9% of all mortality in 2016 (Heron, 2016). The incidence of emergency department (ED) visits by cancer patients has grown over the past years and continues to do so (Delgado-Guay et al., 2015). In additi...
Research and ScholarshipJibran Majeed,(1,2) DNP, ACNP-BC, CCRN, Barbara S. Turner,(1) PhD, RN, FAAN, Deirdre Kelly,(2) ACNP-BC, Chester Poon,(2) Julie A. Thompson,(1) PhD, John Barrett,(3) DNP, FNP-BC, AGACNP-BC, and Gerald A. Soff,(4) MDVenous thromboembolic (VTE) disease in cancer patients is associated with significant morbidity, mortality, and cost (Seroussi et al., 2019). Cancer patients are also at greater risk for hospitalization and bleeding compared with non-cancer patients (Frere et al., 2019; Nene & Coyne, 2017). P...
Review ArticleMatthew Waggoner,(1) MS, John Katsetos,(1) PA-C, Emilee Thomas,(1) MBA, MPH, PA-C, Ilene Galinsky,(2) BSN, MSN, ANP-C, and Heather Fox,(3) PA-CVenetoclax (Venclexta) is a potent, selective, and orally bioavailable small-molecule inhibitor of B-cell lymphoma 2 (BCL-2), a protein that is overexpressed in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML; Jia et al., 2008; Tzifi et al., 201...
Review ArticleKelley D. Mayden,(1) DNP, APRN-FNP, AOCNP®, John M. Kelton,(2) PharmD, Joanne C. Ryan,(2) PhD, RN, and Ali McBride,(3,4) PharmD, BCPS, BCOPBiologics derived from living organisms comprise half of the pharmacologic market share in oncology (Konstantinidou et al., 2020). Manufacturing exact copies of any biologic is impossible, given their inherent variability (Congressional Research Service Report, 2019). Biosimilars are highly simil...
Practice MattersRachel La Costa, MPAS, PA-CIn 2019, a global pandemic emerged from a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), now a ubiquitous household term. COVID-19 has caused significant morbidity and mortality, resulting in nearly 1 million deat...
Prescriber's CornerJessica Davis,(1) PharmD, BCOP, CPP, and Megan Wayman,(2) PharmDIncidence rates of cutaneous melanoma have increased over the past few decades, currently accounting for 1% of all skin cancers. In 2022, an estimated 108,480 new cases will be diagnosed, and 11,990 people are expected to die of melanoma. Metastatic melanoma is associated with high mortality, wit...